AbbVie : to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021

NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab  in Crohn's disease, upadacitinib in ulcerative colitis and... | October 3, 2021

Related Keywords

Japan ,Japanese ,Chiedzo Mpofu ,Remo Panaccione ,Ann Gastroenterol ,Gastroenterol Hepatol ,Prnewswire Abbvie ,Instagram ,Abbvie Ltd ,Linkedin ,Twitter ,European Commission ,Boehringer Ingelheim ,Drug Administration ,Exchange Commission ,University Of Calgary ,European Union ,Allergan ,Facebook ,Abbvie Deutschland Gmbh Co ,Crohn Colitis Foundation Of America ,United European Gastroenterology ,Week Virtual ,Adapted Mayo Score ,Disease Activity Index ,Bowel Disease ,Important Safety Information About ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Global Burden ,Disease Study ,European Gastroenterology Week Virtual ,Inflammatory Bowel ,Colitis Foundation ,Rev Gastroenterol ,Vie Deutschland Gmbh ,Compare Safety ,Adult Participants With Moderate ,Severe Atopic Dermatitis ,Evaluate Efficacy ,Adult Participants With Axial Spondyloarthritis ,Placebo Controlled Study ,Endoscopic Remission ,Subjects With Moderately ,Severely Active Crohn ,Disease Who Have Inadequately Responded ,Are Intolerant ,Participants With Moderately ,Severely Active Ulcerative Colitis ,Participants With Giant Cell Arteritis ,Subjects With Takayasu Arteritis ,Participants With Crohn ,Accessed June ,Study Comparing Risankizumab ,Inadequate Response ,Biologic Therapy ,Placebo Controlled Induction Study ,Severely Active Ulcerative ,Abbvie Inc Stock Exchange ,News ,Information ,Press Release ,North ,021 ,Abbvie ,Oday ,Nnounced ,Few ,Data ,N ,The ,Investigational ,Tse ,F ,Risankizumab ,Upadacitinib ,Ulcerative ,Olitis Abbv Us00287y1091 ,